<DOC>
	<DOC>NCT01734239</DOC>
	<brief_summary>The purpose of this study is to determine if Pneumovax™ 23 (V110) is safe and immunogenic in participants from the Russian population who are 50 years of age and older or 2 to 49 years of age and at increased risk for pneumococcal disease</brief_summary>
	<brief_title>A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>For participants 50 years of age or older: any underlying chronic illness must be in stable condition For participants 2 to 49 years of age: participant has an increased risk for pneumococcal disease as a result of one of the following: chronic cardiovascular disease, chronic pulmonary disease, diabetes mellitus, alcoholism, chronic liver disease, cerebrospinal fluid leaks, functional or anatomic asplenia, sickle cell anemia, living in a special environment or social setting such as crowded, closed communities Male, or female not of reproductive potential, or female of reproductive potential who agrees to remain abstinent or to use 2 acceptable methods of contraception through 6 weeks after study vaccination Received prior vaccination with pneumococcal vaccine Has known or suspected immune dysfunction or conditions associated with immunosuppression, or is receiving immunosuppressive chemotherapy, including longterm systemic corticosteroids Has history of autoimmune disease Received a licensed live virus vaccine within 3 months before or is scheduled within 3 months after study vaccination Received a licensed inactivated vaccine within 28 days before or is scheduled within 28 days after study vaccination Received an investigational drug or other investigational vaccine within 2 months before or is scheduled within 28 days after study vaccination (3 months if a live virus vaccine) Received any blood product or immunoglobulin preparation within 6 months before or 28 days after study vaccination Hospitalized for acute illness within 3 months before study vaccination Is a pregnant woman or nursing mother History of invasive pneumococcal disease or of other culturepositive pneumococcal disease History of fever illness within 3 days before study vaccination Received antibiotic therapy for any acute illness within 7 days before study vaccination Hypersensitivity to any components of the vaccine, including phenol</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>